260 related articles for article (PubMed ID: 10878544)
1. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.
Hobisch A; Rogatsch H; Hittmair A; Fuchs D; Bartsch G; Klocker H; Bartsch G; Culig Z
J Pathol; 2000 Jul; 191(3):239-44. PubMed ID: 10878544
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
3. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue.
Nakashiro K; Hayashi Y; Oyasu R
Oncol Rep; 2003; 10(5):1149-53. PubMed ID: 12883672
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
7. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
8. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
Bostwick DG; Qian J; Maihle NJ
Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue.
Köllermann J; Helpap B
Am J Clin Pathol; 2001 Jul; 116(1):115-21. PubMed ID: 11447740
[TBL] [Abstract][Full Text] [Related]
10. Expression of ezrin in prostatic intraepithelial neoplasia.
Pang ST; Fang X; Valdman A; Norstedt G; Pousette A; Egevad L; Ekman P
Urology; 2004 Mar; 63(3):609-12. PubMed ID: 15028477
[TBL] [Abstract][Full Text] [Related]
11. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.
Uetsuki H; Tsunemori H; Taoka R; Haba R; Ishikawa M; Kakehi Y
J Urol; 2005 Aug; 174(2):514-8. PubMed ID: 16006883
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer.
Ropiquet F; Giri D; Kwabi-Addo B; Mansukhani A; Ittmann M
Cancer Res; 2000 Aug; 60(15):4245-50. PubMed ID: 10945637
[TBL] [Abstract][Full Text] [Related]
14. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.
Vallbo C; Wang W; Damber JE
BJU Int; 2004 Jun; 93(9):1339-43. PubMed ID: 15180634
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
16. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
[TBL] [Abstract][Full Text] [Related]
17. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
18. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
Cardillo MR; Ippoliti F
Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma.
Fixemer T; Remberger K; Bonkhoff H
Prostate; 2003 Feb; 54(2):79-87. PubMed ID: 12497580
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
